Últimas noticias sobre Absci (NASDAQ:ABSI) Bolsa

ABSCI CORP

Absci

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

News

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

ILMN

NTLA

OKLO

PATH

Descubre las recientes decisiones de Ark Invest en energía, defensa y genética, con transacciones millonarias en empresas clave.

Ark Invest adquiere y vende acciones clave en energía, defensa y tecnología genética

Equities

Movers

General

INTC

NVDA

Absci Corporation y AMD se unen para transformar el descubrimiento de medicamentos mediante inteligencia artificial avanzada.

Absci y AMD se asocian para revolucionar el descubrimiento de medicamentos con IA

Absci Corp

JPMorgan&#8217;s Carly Davenport revised her estimates for four major U.S. utilities following <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62fe1e3886af260001885587/carly-davenport">their first-quarter earnings</a>.
The analyst cited new capital expenditure opportunities tied to load growth, evolving regulatory and legislative developments, and the broader impact of policy uncertainty and macroeconomic conditions.
<h2 class="wp-block-heading">Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</h2>
<ul class="wp-block-list">
<li>Duke Energy maintained a Neutral rating, while raising the price target from $122 to $125.</li>
<li>The Charlotte, North Carolina-based company highlighted an incremental nuclear license renewal at the Oconee plant that it could operate into the 2050s, along with upgrades at existing gas, hydro, and nuclear units to add more than 1 gigawatts of capacity, Davenport stated.</li>
<li>"Duke plans to file a merger application for the DEC and DEP utilities to streamline operations and realize cost efficiencies," she wrote.</li>
<li>The company expects the tariff impact at 1%-3% of its five-year capital plan, the analyst added.</li>
</ul>
<h2 class="wp-block-heading">Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</h2>
<ul class="wp-block-list">
<li>Sempra reiterated a Neutral rating, while lifting the price target from $76 to $78.</li>
<li>The San Diego-based company plans to add $12 billion to Oncor's capex plan, Davenport said.</li>
<li>"In California, SDG&amp;E and SoCalGas filed their 2026-2028 cost of capital applications with the CPUC and are anticipating a final decision by the end of 2025 with rates effective by the start of 2026," the analyst wrote.</li>
<li>The company estimates tariff risk as 2%-3% of its base capital plan, given its diverse supply chain, she added.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h2 class="wp-block-heading">WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>)</h2>
<ul class="wp-block-list">
<li>WEC Energy Maintained a Neutral rating, while raising the price target from $101 to $106.</li>
<li>The Milwaukee-based company is bullish about economic growth in its service territories, "especially around the I-94 corridor," Davenport said.</li>
<li>"The company recently filed a new tariff with regulators in Wisconsin specifically for customers with 500 MW or higher loads," the analyst wrote.</li>
<li>The company estimates a 2-3% cost impact from tariffs, she added.</li>
</ul>
<h2 class="wp-block-heading">Dominion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>)</h2>
<ul class="wp-block-list">
<li>Dominion Energy reiterated a Neutral rating, while lifting the price target from $60 to $61.</li>
<li>Davenport said the company has 40 gigawatts of data center capacity in its pipeline and has not witnessed any slowdown in demand in its service territory.</li>
<li>"The company's Virginia Biennial Review filing was submitted at the end of 1Q25, and through the filing, D also proposed a new rate structure for high-volume customers (such as data centers)," the analyst wrote.</li>
<li>The Richmond, Virginia-based company indicated that it was difficult to quantify the tariff impact, as it would depend on the rates at the time of delivery, which is uncertain, she added.</li>
</ul>
At the time of publication on Tuesday:
<ul class="wp-block-list">
<li>Shares of Duke Energyhad declined by 1.60% to $114.01.</li>
<li>Shares of Semprahad risen by 0.44% to $76.03.</li>
<li>Shares of WEC Energyhad declined by 0.65% to $104.29.</li>
<li>Shares of Dominion Energy had declined by 1.06% to $54.30.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45311929/plug-power-partners-up-with-basf-will-use-german-companys-purification-tech-to-liquify-hydrogen">Duke Energy&#8217;s Segment Strength Fuels Q1 Beat, Reaffirms Guidance</a></li>
</ul>
Image: Shutterstock

Analyst Color

Price Target

Reiteration

Analyst Ratings

4 Energy Companies Project Tariff Impact, Analyst Raises Price Targets After Q1 Results

<a href="https://www.bloomberg.com/news/articles/2025-05-13/blackstone-seeks-5-6-billion-to-back-other-private-equity-firms?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-13/blackstone-seeks-5-6-billion-to-back-other-private-equity-firms?embedded-checkout=true</a>

'Blackstone Seeks $5.6B to Back Other Private Equity Firms'- Bloomberg

Benchmark analyst Mark Zgutowicz maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Buy and lowers the price target from $61 to $55.

GLBE

Benchmark Maintains Buy on Global E Online, Lowers Price Target to $55

WIIM

Caterpillar shares are trading higher after Baird upgraded the stock from Neutral to Outperform.

It took more than thirty years, but Japan may finally be on the cusp of a new economic era. After decades of deflation, stagnation, and demographic headwinds, the world&#8217;s third-largest economy is showing real signs of life.
If you&#8217;re still anchored to the &#8220;Lost Decade&#8221; narrative, it&#8217;s time to adjust your compass.
Start with the big picture: inflation in Japan is finally here, and that is a good thing. After years of trying to nudge price levels higher, the Bank of Japan has achieved something that once seemed impossible, a headline inflation rate over 3% and core-core inflation (which strips out food and energy) around 2.8%.
This is not runaway inflation. This is normalization. It is the end of a deflationary mindset that has kept consumers cautious and wages stagnant. Speaking of which, wages are now rising too, thanks to tight labor markets and a shrinking workforce that has finally given employees some bargaining power. Real wage growth is still lagging a bit, but the trajectory is right.
On the monetary policy front, the Bank of Japan made headlines in March 2024 by finally ending its negative interest rate policy. That marked the first rate hike in 17 years and the symbolic end of an era of extraordinary easing. It also marked Japan&#8217;s return to monetary policy normalcy. Gone is the yield curve control regime. In its place is a traditional rate targeting system like those used in the U.S. and Europe. Japan is no longer the outlier. It is rejoining the global financial mainstream.
Even the once anemic GDP growth rate is improving. In 2023, real GDP expanded by 1.9%, with Q4 2024 showing 1.1% year-over-year growth. That may not sound spectacular, but given Japan&#8217;s aging population and past headwinds, it&#8217;s more than respectable.
The trade deficit has also narrowed sharply, with record exports (particularly in autos) and a booming services surplus. Meanwhile, foreign investment income continues to pile up, pushing the current account solidly into surplus territory.
Then there&#8217;s the stock market. Japan&#8217;s equity market has finally caught fire. After languishing for over three decades below its 1989 high, the Nikkei 225 finally eclipsed that peak in 2024, closing in on 42,000 and leading the world in equity performance.
That move wasn&#8217;t driven by speculative mania, but by real earnings growth, aggressive share buybacks, and long-overdue reforms in corporate governance. The Tokyo Stock Exchange has pushed companies to raise ROE and address chronically low price-to-book ratios. Firms are responding. Cross-shareholdings are down, boards are becoming more independent, and management teams are starting to think more like owners.
Foreign investors are noticing too. Warren Buffett made headlines by boosting his stakes in Japan&#8217;s trading houses. Institutions across the globe are following suit, shifting exposure out of China and into Japan. The yen, once battered by interest rate differentials, is now finding its footing as the BoJ lifts off zero.
In KKR&#8217;s 2025 Outlook, they specifically highlight Japan as a key opportunity area: &#8220;We see opportunities in inter-company holdings. There is an accelerating unwind of Japanese strategic holdings within the corporate sector, encouraging a wave of stock buybacks. Additionally, we advocate for more active capital management, including backing companies transitioning from capital-heavy to capital-light models through Private Equity.&#8221;
A stable to strengthening yen, combined with structural reforms and a new era of pricing power, makes for a very interesting setup.
Look, Japan still has challenges. The population is shrinking, productivity growth could be stronger, and public debt remains sky-high. But for once, those aren&#8217;t the only parts of the story. Japan has exited the deflation trap. The stock market is not only alive but leading the pack. Policy is normalizing. Corporate governance is improving. Wages are moving. Investors are finally being rewarded.
Bottom line: Japan isn&#8217;t the basket case it used to be. It&#8217;s becoming a compelling story again—one that belongs in any serious global investor&#8217;s playbook. If you&#8217;re looking for value, reform, and upside, it might be time to look East. Japan is back in the game.
Okay. Melvin, we get it.
Can we move on now?
No.
No, we cannot.
There is every reason to believe that after 15 years of US markets flying high and long periods of Japan underperforming, we may see a reversal of fortune.
It is time to look outside the United States for high return opportunities.
Let&#8217;s start with the five trading companies Buffett has been buying and suggested last week that Berkshire will own for at least 50 years.
They are ITOCHU (Ticker: ITOCY), Marubeni (Ticker: MARUY), Mitsubishi (Ticker: MSBHF), Mitsui (Ticker: MTSFY), and Sumitomo (Ticker: SSUMY).
These companies are in a wide range of businesses including finance, energy, metals, machinery, chemicals, food, and textiles.
They are cheap based on both earnings and assets and have attractive dividend yields.
The other stock that seems like a layup from here is Kansai Electric (KAEPY). Kansai is the second largest industrial region of Japan and contains the metropolitan region of Osaka, Kobe, and Kyoto, which is the second largest in Japan.
Looking beyond the headlines, Kansai Electric Power stands as a textbook example of how traditional utilities can transform themselves into multi-dimensional businesses that weather economic cycles better than their one-trick-pony counterparts.
As Japan&#8217;s second-largest electric utility serving the industrial heartland of Osaka, Kyoto, and Kobe, Kansai Electric has been quietly building a business model that extends far beyond simply keeping the lights on. While Wall Street and financial media remain fixated on flashier tech names, real value investors understand that essential services with diversified revenue streams often deliver steadier returns.
Kansai operates through four distinct segments &#8211; energy, power transmission, IT/telecommunications, and lifestyle solutions &#8211; creating multiple paths to profitability regardless of economic conditions.
Their telecom operations under the &#8220;eo Hikari&#8221; brand and &#8220;mineo&#8221; mobile business represent the kind of steady cash flow businesses value investors prize.
What particularly catches my attention is their international expansion strategy. Unlike companies rushing into fashionable markets, Kansai made calculated moves, starting with hydro projects in the Philippines and recently taking a significant 49% stake in a German offshore wind project. This methodical approach to capital allocation, putting money to work in undervalued assets with predictable returns, is reminiscent of Buffett and Munger in their heyday.
On the energy technology front, they&#8217;re investing $7 billion to expand renewable capacity. Their research focuses on practical technologies like carbon capture, small modular reactors, and grid optimization. They are not chasing headline-grabbing moonshots that rarely deliver returns.
Perhaps most interesting is their hydrogen and ammonia strategy, targeting 30% of Japan&#8217;s hydrogen supply chain by 2050. While everyone else is busy chasing the latest AI startup, Kansai is quietly positioning itself in infrastructure that will be essential regardless of which way the technological winds blow.
Compared to US utility companies, shares of Kansai Electric are cheap. The stock is currently trading at 64% of tangible book value and less than 5 times free cash flow.
The yield is currently about 3%.
We are not done with Japan yet. There are still plenty of smaller cap companies that are worth exploring as we look for alternatives to the potential lost decade here in the US.

Opinion

ITOCY

MARUY

MSBHF

MTSFY

SSUMY

Under the Radar: From Deflation to Dividend Machines — Japan's Market Turns a Corner

B of A Securities analyst Jeffrey Spector maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Buy and raises the price target from $368 to $380.

B of A Securities Maintains Buy on Public Storage, Raises Price Target to $380

<a href="https://www.bloomberg.com/news/articles/2025-05-13/united-air-warns-flyers-of-reduced-newark-service-through-summer?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-13/united-air-warns-flyers-of-reduced-newark-service-through-summer?embedded-checkout=true</a>

'United Air Warns Flyers of Reduced Newark Service Through Summer'- Bloomberg

B of A Securities analyst Jeffrey Spector maintains Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) with a Neutral and raises the price target from $155 to $161.

B of A Securities Maintains Neutral on Extra Space Storage, Raises Price Target to $161

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 10 years by 11.23% on an annualized basis producing an average annual return of 21.91%. Currently, Murphy USA has a market capitalization of $8.70 billion. 
Buying $1000 In MUSA: If an investor had bought $1000 of MUSA stock 10 years ago, it would be worth $7,305.16 today based on a price of $439.48 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747155115_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MUSA

Here's How Much You Would Have Made Owning Murphy USA Stock In The Last 10 Years

JPMorgan analyst Doug Anmuth <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained an Overweight</a> rating on Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a price target of $1,150 on Monday.
Netflix shares are +30% above post-tariff lows, significantly outperforming the SPX +15%, driven by the streaming giant&#8217;s defensive subscription nature &amp; streaming leadership against macro and tariff uncertainty, Anmuth noted.
The analyst said some of that may reverse shortly as trade relief shifts investors more to tariff-impacted names that have lagged in recent weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" rel="noreferrer noopener">Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</a>
More fundamentally, heading into Netflix&#8217;s Upfronts this week, he expects the company to provide updated Ad Tier MAUs, announce further expansion of the Netflix Ads Suite across international markets, and highlight key Live/Sports content.
Anmuth remains bullish on Netflix&#8217;s growing Ad Tier scale and projected Ad Tier subscribers of 60 million+ by the end of 2025, which ties to 140 million+ MAUs, assuming ~2.3 times MAUs or subscribers.
Now that Netflix has reached sufficient scale, the company is shifting its focus more to monetization. The analyst projected advertising revenue (ex-subscription) of $3.0 billion in 2025, more than doubling from $1.4 billion in 2024. Beyond advertising, the 2025 content slate remains strong, with key second-quarter releases including &#8220;Nonnas,&#8221; &#8220;Sirens,&#8221; &#8220;Big Mouth&#8221; Season 8, &#8220;Fear Street: Prom Queen,&#8221; &#8220;Ginny &amp; Georgia&#8221; Season 3, &#8220;Tires&#8221; Season 2, &#8220;FUBAR&#8221; Season 2, and &#8220;Squid Game&#8221; Season 3.
Potential tariff implementation on films produced outside the U.S. has been a growing topic, but the implementation remains unclear, and it is difficult to size the potential financial impact.
Anmuth noted that Netflix produces original content across 50+ countries globally, and 3P articles suggest that 50%+ of content is produced internationally. However, Netflix&#8217;s contributions to the U.S. are significant, with 9k+ full-time U.S. employees, 2.2 million square feet of corporate office space in the U.S., and 3.1 million square feet of studio space across 60 U.S. soundstages.
Anmuth remained positive on Netflix, and his bull thesis reflects healthy double-digit revenue growth in both fiscal 2025 and 2026, continued operating margin expansion while increasing investments in content, ads, and gaming, multi-year free cash flow ramp on improving profit and cash content discipline, with growing buybacks, the company&#8217;s strong streaming leadership position, the potential to become global TV as Netflix expands its ~308 million member base (700 million+ global audience) across the 750 million+ broadband HHs ex-Russia &amp; China.
Anmuth projected average 2025 and 2026 growth of +13% for foreign-exchange-neutral revenue, +22% for operating income, +24% for GAAP EPS, and +30% for free cash flow, which the analyst noted supports Netflix&#8217;s premium valuation.
Price Action: NFLX stock is up 3.1% to $1,144.61 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo: Shutterstock

Entertainment

NFLX

Netflix Rally Could Cool As Trade Relief Shifts Focus, JPMorgan Still Bullish

China-based&nbsp;JD.com,&nbsp;Inc.&nbsp;(NASDAQ:&nbsp;JD) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45369198/jd-com-announces-first-quarter-2025-results" rel="noreferrer noopener">fiscal first-quarter</a> results on Tuesday. The company reported a quarterly revenue growth of 15.8%&nbsp;year-over-year&nbsp;to $41.5 billion, beating the&nbsp;analyst consensus estimate of $40.2 billion.
JD posted&nbsp;an adjusted net income per ADS of $1.16, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $1.05.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs" rel="noreferrer noopener">US Listed Chinese Stocks Rally As Countries Agree To Ease Import Tariffs</a>
<h1 class="wp-block-heading">JD Segment Performance</h1>
JD.com&#8217;s&nbsp;net product revenue increased by 16.2%&nbsp;Y/Y&nbsp;at $33.39 billion. Net service revenues rose 14.0%&nbsp;Y/Y&nbsp;to $8.1 billion.&nbsp;
JD Retail revenue climbed 16.3%&nbsp;Y/Y&nbsp;to $36.36 billion, Logistics revenue gained 11.5% Y/Y to $6.47 billion, and the new business revenues grew 18.1% Y/Y to $793 million.
JD.com&#8217;s marketing expenses rose 13.9% to $1.5 billion in the quarter, forming 3.5% of revenues, down by 10 bps.
<h1 class="wp-block-heading">Margins</h1>
Operating margin was 3.5% for the quarter, compared to 3.0% Y/Y. Adjusted operating margin improved by 50 bps Y/Y to 3.9%. JD Retail&#8217;s operating margin rose 80 bps to 4.9%.&nbsp;
Adjusted EBITDA increased 27.0% Y/Y to $1.9 billion, with a 4.6% margin, up by 50 bps.
JD.com used $2.98 billion in free cash flow for the quarter and $2.52 billion in operating cash flow. The company held $28.0 billion in cash and equivalents as of March 31, 2025.
CEO Sandy Xu attributed the quarterly results to improving consumer sentiment and continued enhancements to JD&#8217;s supply chain capabilities and user experience.
Price Action: JD stock is up 5.31% at $37.97 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45365162/cathie-wood-makes-bullish-move-on-baidu-ark-adds-30k-shares-amid-china-us-trade-thaw" target="_blank" rel="noreferrer noopener">Cathie Wood Makes Bullish Move On Baidu: Ark Adds 30K+ Shares Amid China-US Trade Thaw</a></li>
</ul>
Photo by Freer via Shutterstock

Asia

Earnings

Tech

JD.com Clocks Strong Q1 Retail And Logistics Growth Fueled By Cash Burn

BMO Capital analyst Rufus Hone maintains Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) with a Market Perform and lowers the price target from $7 to $5.

RPAY

BMO Capital Maintains Market Perform on Repay Holdings, Lowers Price Target to $5

UBS analyst Joshua Spector maintains Orion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OEC#NYSE">OEC</a>) with a Buy and lowers the price target from $17 to $15.

UBS Maintains Buy on Orion, Lowers Price Target to $15

BMO Capital analyst Etzer Darout maintains Terns Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) with a Outperform and lowers the price target from $26 to $15.

TERN

BMO Capital Maintains Outperform on Terns Pharma, Lowers Price Target to $15

Johnson & Johnson shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $169 to $153.

UBS analyst Michael Goldsmith maintains Alpine Income Property Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Neutral and lowers the price target from $17 to $16.

PINE

UBS Maintains Neutral on Alpine Income Property Tr, Lowers Price Target to $16

AMAT

ASML

AVGO

KLAC

LEDS

LRCX

LSCC

MCHP

MRVL

NXPI

QCOM

RMBS

SIMO

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSEM

Shares of semiconductor and chip stocks are trading higher as investors assess US-China trade progress and Saudi Arabia deals.

President Donald Trump on Monday signed a sweeping executive order aimed at drastically reducing prescription <a href="https://www.benzinga.com/topic/drug-prices">drug prices in the U.S. </a>
What Happened: y tying them to the lowest prices paid in comparable foreign countries — a policy known as <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45381118/cvs-health-cigna-stocks-dip-tuesday-whats-going-on">&#8220;most-favored-nation&#8221; pricing.</a>
The executive order is <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a response</a> to what Trump described as &#8220;unreasonable or discriminatory&#8221; practices abroad. 
"In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home," Trump said in <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a statement</a>. 
Drug manufacturers have 30 days to voluntarily lower prices for prescription drugs in the U.S. to match those paid in other advanced nations.&nbsp;
If companies do not comply, the Department of Health and Human Services, led by Robert F. Kennedy Jr., is tasked with developing rules to enforce most-favored nation (MFN) pricing or other regulatory measures.&nbsp;
The HHS is also instructed to establish mechanisms for Americans to purchase drugs directly from manufacturers at the MFN price, bypassing pharmacy benefit managers (PBMs) and other intermediaries.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom?utm_source=articleShare">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>&nbsp;
Why It Matters: The executive order is a rare show of common ground between the Trump administration and Democratic leaders like Senator Bernie Sanders, who has long fought for laws aimed at making medicine more affordable.
And Trump has tried this before. During his first term, he signed a similar <a href="https://trumpwhitehouse.archives.gov/presidential-actions/executive-order-lowering-drug-prices-putting-america-first-2/">order</a> that the courts ultimately blocked after the pharmaceutical industry lobbied against it.
Sanders fears the same thing might happen again. In a <a href="https://bsky.app/profile/did:plc:upw5n2uwhzubjajdtqaufsek/post/3loyh44tra225?ref_src=embed&amp;ref_url=https%253A%252F%252Fwww.commondreams.org%252Fnews%252Ftrump-executive-order-drug-prices">post</a> on the Bluesky social network, he agreed that it is &#8220;an outrage that the American people pay, by far, the highest prices in the world for prescription drugs.&#8221;
&#8220;As Trump well knows, his executive order will be thrown out by the courts,&#8221; said Sanders. &#8220;If Trump is serious about making real change rather than just issuing a press release, he will support legislation I will soon be introducing to make sure we pay no more for prescription drugs than people in other major countries. If Republicans and Democrats come together on this legislation, we can get it passed in a few weeks.&#8221;
Pharmaceutical stocks dropped in Monday's premarket trading, but recovered into positive territory by the market close.
Analysts and investors decided the order was less-specific than feared and likely to be challenged in court. 
"A drug pricing announcement had been expected for a while now and had weighed on stocks in this sector, so the official executive order doesn&#8217;t seem to be impacting sentiment too much,&#8221; said James Harlow, senior vice president at Novare Capital Management, per Reuters.&nbsp;
In contrast, Trump&#8217;s comments of &#8220;cutting out the middlemen&#8221; weighed on shares of companies that own pharmacy benefit managers like The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and UnitedHeath Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).&nbsp;
"I would cut out the middlemen," Trump said. "Everybody should equalize. Everybody should pay the same price."
Shares of UnitedHealth plunged Tuesday after<a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance"> the company</a> pulled its 2025 outlook, citing that care activity continued to accelerate and CEO Andrew Witty unexpectedly resigned.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a>
What To Watch: The executive order threatens the PBM business model by enabling direct-to-consumer drug purchases, which could significantly reduce the need for PBMs&#8217; negotiating and administrative services. However, legal experts have raised concerns about the legality of direct-to-consumer sales.&nbsp;
"This order's suggestion of broader or direct-to-consumer importation stretches well beyond what the statute allows," warned health policy lawyer, Paul Kim, per the New York Post.&nbsp;
Investors in the healthcare sector may choose to mitigate risk and exposure to PBMs through a diversified healthcare ETF like the SPDR Select Health Care Sector Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) which holds shares of pharmaceuticals, health care equipment and supplies and health care providers.&nbsp;
An ETF like the iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITI#NYSE">ITI</a>) which tracks the Dow Jones U.S. Select Medical Equipment Index and invests in leading U.S. medical device companies also offers exposure to the healthcare industry while reducing exposure to pharmaceutical benefit managers.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45319531/cathie-wood?utm_source=articleShare">Cathie Wood Says AI Will &#8216;Disrupt The Traditional World Order&#8217; And Replace Search Engines Like Google</a>&nbsp;</li>
</ul>
Image: Shutterstock

Large Cap

Sector ETFs

Specialty ETFs

Health Care

Politics

ETFs

Trump Again Promises Lower Drug Prices By 'Cutting Out Middlemen' Like UnitedHealth, CVS: Will It Work This Time?

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) have posted strong gains over the past week, rallying more than 25% as Bitcoin hovers near all-time highs, fueling momentum across the meme coin sector.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2387</td>
<td>+2%</td>
<td>+43%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001603</td>
<td>+0% </td>
<td>+28% </td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td> $0.00001438</td>
<td>+4% </td>
<td>+84% </td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Tardigrade pointed out that Dogecoin is entering the final stage of its Cycle 3, typically the most explosive phase, and says momentum is building fast.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> is finalizing Cycle 3 &#x1f525; This is the most powerful move in the cycle. Let&#39;s see how it goes &#x1f680;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/ut8s0LiMPp">pic.twitter.com/ut8s0LiMPp</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1922216007000813797?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Rekt Capital <a href="https://x.com/rektcapital/status/1922009907198328913">highlighted</a> DOGE currently retesting a key pre-halving resistance zone as new support. If this level holds, the next upside target is $0.27.
Meanwhile, CryptoGuru <a href="https://x.com/BDCryptoGuru/status/1922242833328570681">noted</a> Shiba Inu has broken out cleanly from a descending channel with a 68% move. 
As long as the current pullback holds above this level, the bullish setup remains intact. 
He advises watching for volume and support confirmation for potential continuation.
Statistics: Glassnode data shows DOGE futures open interest up 63.9% over the past week, from $989 million to $1.62 billion, even as price momentum cools. This signals heightened speculative interest
Shibburn data shows that 14.6 million SHIB tokens were burned in the past 24 hours, continuing the trend of reducing supply, a key factor that can contribute to upward price pressure.
Shibariumscan reports daily transactions rose from 4.16 million to 4.21 million within a single day, signaling growing on-chain activity.
According to IntoTheBlock, Shiba Inu also saw a massive 214.3% spike in large transaction volume over the same period. 
Daily active addresses climbed 13.8%, while high-value transactions (over $100,000) jumped from 115 to 195 — underscoring rising interest from larger players and increasing network engagement.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45314812/mark-cuban-slams-memecoins-says-they-set-a-bad-example-for-new-crypto-investors">Mark Cuban Slams Memecoins, Says They Set A &#8216;Bad Example&#8217; For New Crypto Investors</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin, Shiba Inu Surge Over 25% In 7 Days: What Is Going On?

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Neutral and lowers the price target from $14 to $12.

UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $12

Small Cap

Press Releases

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape

Absci to Participate in the TD Cowen 45th Annual Health Care Conference

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

Absci to Participate in Upcoming Investor Conferences

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

Comments

Absci

Noticias

Últimas noticias sobre Absci (NASDAQ:ABSI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL